Literature DB >> 15166225

Mechanisms of interactions of factor X and factor Xa with the acidic region in the factor VIII A1 domain.

Keiji Nogami1, Jan Freas, Chandrashekhara Manithody, Hironao Wakabayashi, Alireza R Rezaie, Philip J Fay.   

Abstract

The 337-372 sequence of the factor VIIIa A1 subunit contains interactive sites for both zymogen factor X and the active enzyme, factor Xa. Solid phase binding studies indicated that factor Xa possessed a >20-fold higher affinity for the isolated A1 subunit of factor VIIIa compared with factor X. Heparin completely inhibited zero-length cross-linking of the 337-372 peptide to factor Xa but not to factor X. In the presence of calcium, factor Xa showed greater affinity for heparin than factor X. Studies using factor Xa mutants in which heparin-binding exosite residues were individually replaced by Ala showed that the R240A mutant was defective in recognition of the Lys36 cleavage site, generating the A137-372 intermediate with approximately 20% the catalytic efficiency of wild type. This defect likely resulted from an approximately 4-fold increase in Km for the A1 substrate because kcat values for the wild type and mutant were equivalent. Cleavage of the A1-A2 domain junction by factor Xa R240A was not blocked by the 337-372 peptide. Studies using mutant factor VIII where clustered acidic residues in the 337-372 segment were replaced by Ala showed that a factor VIIIa D361A/D362A/D363A mutant possessed a approximately 1.6-fold increase in Km for factor X compared with wild type. However, similar Km values were observed for recombinant factor X and R240A substrates. These results indicate that the binding regions of factor X and factor Xa for A1 domain overlap and that both utilize acidic residues 361-363. Furthermore, factor Xa but not factor X interacts with high affinity at this site via residues contained within the heparin-binding exosite of the proteinase.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15166225     DOI: 10.1074/jbc.M405537200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Study on the efficacy and safety of Xueyou Mixture in treating hemophilia.

Authors:  Shan-xi Liu; Lin Jiang; Yi-guo Liu; Yue-qin He; Xin Liang; Wei-wei Kong; Jing Chen
Journal:  Chin J Integr Med       Date:  2007-06       Impact factor: 1.978

2.  Role of P1 residues Arg336 and Arg562 in the activated-Protein-C-catalysed inactivation of Factor VIIIa.

Authors:  Fatbardha Varfaj; Julie Neuberg; P Vincent Jenkins; Hironao Wakabayashi; Philip J Fay
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

3.  Sequences flanking Arg336 in factor VIIIa modulate factor Xa-catalyzed cleavage rates at this site and cofactor function.

Authors:  Jennifer P DeAngelis; Hironao Wakabayashi; Philip J Fay
Journal:  J Biol Chem       Date:  2012-03-12       Impact factor: 5.157

4.  Does plasmin have anticoagulant activity?

Authors:  Jane Hoover-Plow
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

Review 5.  Characterization of factor VIII inhibitors.

Authors:  Midori Shima
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

Review 6.  Factor VIII structure and function.

Authors:  Philip J Fay
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

7.  Ixolaris binding to factor X reveals a precursor state of factor Xa heparin-binding exosite.

Authors:  Robson Q Monteiro; Alireza R Rezaie; Jong-Sup Bae; Eric Calvo; John F Andersen; Ivo M B Francischetti
Journal:  Protein Sci       Date:  2007-11-27       Impact factor: 6.725

8.  Identification of 31 novel mutations in the F8 gene in Spanish hemophilia A patients: structural analysis of 20 missense mutations suggests new intermolecular binding sites.

Authors:  Adoración Venceslá; María Angeles Corral-Rodríguez; Manel Baena; Mónica Cornet; Montserrat Domènech; Montserrat Baiget; Pablo Fuentes-Prior; Eduardo F Tizzano
Journal:  Blood       Date:  2008-01-09       Impact factor: 22.113

9.  Interaction between mouse adenovirus type 1 and cell surface heparan sulfate proteoglycans.

Authors:  Liesbeth Lenaerts; Wim van Dam; Leentje Persoons; Lieve Naesens
Journal:  PLoS One       Date:  2012-02-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.